NorthWest Biotherapeutics Inc (NWBO)

[beachhyena]

It seems to me that more and more articles are looking at DCVAX-L as a promising therapy.
Here is another new study that mentions DCVAX-L as promising. Something in the air maybe.

Published Sept 15th.

From Article..

We coupled our preclinical observations on cDC1 with studies in patients. There has been significant work on the use of DC in GBM immunotherapy. Specifically, DCVax-L is a DC therapy vaccine platform in which autologous monocyte-derived DC are loaded with a patient’s tumor lysate and transferred back into the patient (79). Studies have also demonstrated the capacity to enhance the migratory activity of these DC by pre-conditioning to potentially improve patient outcomes (80). While these approaches are promising, we focused not on DC as a therapeutic approach in this study, but rather on the location and phagocytic function of endogenously arising cDC subsets in patients undergoing brain tumor surgery. We identified CD141+ cDC1, CD1c+ cDC2, CD14+ monocytes, and CD16+ monocytes, as well as CD4+ and CD8+ T cells in GBM.
These findings extend our observations in mice, in which we observed that the tumor is infiltrated with DC far beyond the normal background for steady state brain.

Article at:

https://www.biorxiv.org/content/10.1101/2021.09.13.460088v1.full.pdf